700196A gamma camera having improved spectral resolutionClosedGRD Proof of MarketInnovate UKThis market study relates to developments that Symetrica could make towards improving the performance of gamma-cameras that are currently used in many hospitals world-wide. These cameras provide vitally important diagnostic information to clinicians in many branches of medicine especially, Cardiology, Oncology and Neurology. We believe that the combination of our unique spectrum-processing technology with existing gamma-cameras, will provide images that have improved contrast, greater sensitivity and create the possibility of generating simultaneous, ‘multi-colour’ gamma-ray images of a patient. This could remove the need for patients to undergo repeated measurements several hours apart in order to collect the same information. These improvements could: (a) Increase the accuracy of diagnosis and thereby lead to more precise treatment plans, (b) Improve the sensitivity of the camera and provide the capability to conduct two or more investigations in parallel. This could lead to an increase in the throughput of the Departments of Nuclear Medicine, thus reducing cost and also a reduction in the radiation dose to which patients are exposed. This market study will: (a) Identify which diagnostic procedures would most benefit from the potential improvements achievable in gamma-camera performance, (b) Scope the financial and clinical value of the performance improvements for each procedure, (c) Quantify the scale and potential value of the addressable market for the improved gamma-camera technology, (d) Assess the potential routes to market for the new technology.